Psilocybin Microdosing Schedule: Fadiman, Stamets, And
The most popular advice about a psilocybin microdosing schedule is also the most misleading: find the correct protocol and follow it exactly. There isn't an official standard dose or calendar. The Fadiman pattern is influential, the Stamets-style rhythm is widely discussed, and clinical researchers are testing carefully timed regimens, but none guarantees the same result for every person.
A workable schedule is a personal experiment, not a loyalty test. Your goal, sensitivity, baseline mood, sleep, obligations, mushroom material, and response to each session all matter. The useful question isn't “Which protocol is best?” It's “Which pattern produces the clearest benefit with the least disruption, and can I tell that from my records?”
Table of Contents
- Why There Is No Standard Psilocybin Microdosing Schedule
- Comparing the Major Microdosing Protocols
- Choosing Your Dose Size and Daily Timing
- Managing Rest Days and Tolerance Breaks
- Tracking Your Results to Find What Works
- Safety Considerations and Legal Realities
Why There Is No Standard Psilocybin Microdosing Schedule
A fixed calendar can reduce uncertainty, but it cannot account for every person's response. The evidence supports treating a correct schedule as a working hypothesis rather than a universal rule. A 2026 NIH-linked review describes the commonly used idea of a microdose as 10% or less of a full dose and reports that the Fadiman protocol was the most frequently reported regimen among regular microdosers. Only 24.3% used it, so familiarity does not make it a consensus. (NIH-linked review of microdosing practices)
Broader evidence also shows wide variation. Survey research found that microdosers most commonly reported psilocybin use 3 to 5 times per week, often at 0.1 to 0.3 grams of dried mushrooms. These results describe reported behavior, while individual response still depends on sensitivity, mood, sleep, obligations, material, and the goal being tested. (Survey research on microdosing practices)
Protocol popularity isn't proof
The Fadiman schedule developed through informal experimentation. The Stamets pattern also gained attention through community practice and theory, rather than a definitive head-to-head trial showing that it outperforms other calendars. A schedule may be memorable, repeatable, and useful for one person while still lacking clinical validation.
Controlled research has begun testing explicit timing patterns, but the designs differ. One randomized, double-blind, placebo-controlled mushroom study used a 2-week active-dose phase, a 2-week placebo phase, and 1 week without measurements, with 0.5 grams of dried mushrooms per active dose. Other trials tested 2 milligrams once weekly, while a citizen-science study followed 191 participants over a 4-week dosing period with 2 microdoses per week in the active group. (Controlled microdosing study designs)
These studies show that researchers can examine dose timing systematically. They do not identify one public schedule as the winner. Individual differences matter when the target is mood, focus, creativity, sleep, or emotional steadiness, as explained in this guide to individual variation.
Treat the calendar as a hypothesis
Choose one established framework, keep other variables stable, and define helpful and harmful outcomes before starting. A creative worker might track idea generation and social ease. Someone evaluating mood may prioritize emotional stability and sleep. An unpredictable routine may make flexible timing more informative than forcing a dose on a stressful day.
Record the schedule, context, perceived effects, sleep, and any unwanted changes. Review the pattern after enough observations to distinguish a repeatable response from an isolated good or bad day.
A schedule earns its place through clear results and manageable disruption. Stimulation, anxiety, distraction, emotional flatness, or impairment are reasons to stop and reassess, regardless of how established the protocol sounds.
Comparing the Major Microdosing Protocols
No calendar has emerged as the standard for psilocybin microdosing. The main options are Fadiman, Stamets-style, and custom or hybrid scheduling. Their practical difference is the spacing between dose days and the amount of structure imposed on the week.
The Fadiman protocol uses one dosing day followed by two days off, often called an “every third day” cadence. This design makes observation relatively straightforward. Dose days and non-dose days remain distinct, giving you clearer comparison points for mood, focus, or energy. The rest days also show whether an effect persists beyond the dosing day. A review of the schedule in published microdosing literature describes this cadence, while leaving open questions about how it compares with other calendars. (Every-third-day schedule in the literature)
The Stamets-style schedule is commonly described as four days on and three days off, sometimes combined with lion's mane and niacin. Its theory emphasizes repeated exposure and a proposed “stack” associated with neuroplasticity, but controlled research on the combined approach remains limited. A 2024 qualitative study reported the Fadiman protocol among 38% of respondents, compared with 8% for a five-days-on, two-days-off Stamets-style schedule and 2% for a four-days-on, three-days-off schedule. These figures describe reported practice, not comparative effectiveness. (Qualitative study of reported schedules)
| Protocol | Dosing Schedule | Core Rationale | Best For |
|---|---|---|---|
| Fadiman | One day on, two days off | Clear dose and comparison days, with regular rest | Beginners who value simple tracking |
| Stamets-style | Four days on, three days off | More repeated exposure and a structured weekly rhythm | People who can tolerate a denser routine and want a predictable workweek pattern |
| Custom or hybrid | Adjusted around goals, response, and obligations | Personal fit over protocol loyalty | Unpredictable schedules or people testing specific outcomes |
Match structure to your week
Fadiman suits people who want frequent rest and cleaner comparisons. A four-days-on pattern can concentrate doses during working days, though repeated exposure makes dose-day effects harder to separate from cumulative effects. Custom scheduling works best when it adapts a recognized framework and preserves consistent records.
A useful test compares Fadiman with a lower-frequency weekly pattern, or changes dose timing while keeping the cadence stable. Change one variable at a time. Altering the schedule, dose, supplements, sleep routine, and caffeine together makes the outcome difficult to interpret.
For a practical explanation of the Stamets approach, see MicroTrack's guide to the Paul Stamets stack. Choose the protocol that fits your obligations, then judge it by repeatable outcomes, tolerable disruption, and the quality of your tracking rather than by its reputation.
Choosing Your Dose Size and Daily Timing
Dose size and time of day are separate variables. A schedule may look sensible on paper yet fail when the amount is too noticeable, the timing disrupts sleep, or the day is too demanding to interpret subtle changes. Since no universal protocol exists, treat both variables as test conditions rather than fixed rules.
Survey research describes commonly reported dried-mushroom amounts of 0.1 to 0.3 grams, while available evidence does not establish a universal dose. Potency differs between mushroom material, and a guideline such as 10% or less of a full dose offers no clinical standard for individual use. (Evidence on reported dose ranges and the lack of a standard)
Calibrate conservatively
Start with the lowest practical amount available to you, then allow enough time to observe it before making an adjustment. The goal is a sub-perceptual, non-impairing threshold. Obvious perceptual changes, racing thoughts, marked anxiety, or impaired concentration indicate that the amount is too high for a microdose.
Keep the preparation and measurement method consistent throughout a test period. Uneven potency weakens comparisons, and changing the mushroom material can make an otherwise careful record difficult to interpret. If you feel unwell, skip the next session instead of compensating with a larger or earlier dose.
Morning dosing is often easier to assess because it separates the session from bedtime and places observations alongside daytime tasks. Late morning or early afternoon may fit a creative-work test, provided sleep remains unaffected. A fixed time improves comparisons because each dose is evaluated under similar conditions.
Let real life override the calendar
Skip a planned session before travel, an important meeting, a social obligation, or a night when sleep is already disrupted. Record the reason and resume when baseline conditions are steadier. That record helps distinguish schedule effects from ordinary changes in workload, sleep, or stress.
Do not dose on a day involving driving, machinery, or safety-critical work if you feel altered. A schedule that requires concealed impairment or continued use through distress needs to be stopped and reassessed. The most useful protocol is the one that produces interpretable observations without compromising judgment or daily safety.
Managing Rest Days and Tolerance Breaks
Rest days make a schedule interpretable. They provide sober observations, reduce pressure to increase the amount, and show whether a perceived benefit continues beyond the dosing day. The commonly described every-third-day pattern builds in a washout day because effects may extend past the session. For the peer-reviewed discussion of every-three-day dosing, see this review of psychedelic microdosing.
Daily dosing is a weak starting point for a self-experiment. Classic psychedelics can produce tolerance, and repeated sessions may make effects less distinct while encouraging escalation. Watch for a fading cognitive lift, flatter mood, disrupted or more variable sleep, or an urge to take more to recreate an earlier response. Any of these signs calls for a pause and review of the schedule.
Use breaks as decision points
A perfect streak is a poor measure of success. Useful evidence comes from enough sober observations to judge whether the practice fits your life. If benefits become harder to distinguish or side effects increase, stop and reassess frequency rather than adding sessions.
Clinical research is also testing lower-frequency schedules. A phase II major depressive disorder protocol planned 2 milligrams once weekly for 4 weeks, followed by another 4 weeks at the same weekly frequency, with participants randomized against placebo. (Phase II microdosing protocol) A separate registry describes 2 or 3 milligrams daily, 4 days per week, for 2 consecutive weeks, followed by 1 week without doses in its open-label extension. (Clinical trial registry schedule)
These schedules are designed for research contexts. They illustrate why greater frequency should not automatically be treated as greater effectiveness. Use the same principle when comparing personal schedules: change one feature at a time, then allow enough rest days to observe the result.
A longer pause can clarify psychological reliance. If work, creativity, socializing, or mood regulation feels impossible without dosing, stop and seek support instead of refining the calendar.
Tracking Your Results to Find What Works
A schedule can feel effective because expectations shape perception. Start tracking before the first dose, using a quiet baseline period to observe your usual mood, focus, sleep, anxiety, and productivity without changing the routine. This gives later ratings a reference point.
Create a calendar for dose days, rest days, skipped sessions, and protocol changes. Define the outcomes in advance. Separate ratings for mood, focus, sleep, and anxiety enable direct comparison across weeks and expose trade-offs that a single overall impression can hide.
Build a repeatable log
Use the same check-in windows each day. A morning entry can cover baseline mood, energy, sleep quality, and intention. An evening entry can record focus, social ease, anxiety, side effects, and whether the day's work improved.
A simple 1-to-10 scale keeps entries quick, while free-text notes retain context. Record unusual caffeine intake, stressful events, illness, travel, and missed sleep. These factors can create apparent patterns unrelated to psilocybin.
| Metric | Scoring Method | What to Watch For |
|---|---|---|
| Mood baseline | Consistent 1-to-10 morning rating | Whether improvement appears only on dose days or carries into rest days |
| Focus | 1-to-10 rating plus a brief task note | Sustained attention versus restless activity |
| Creative output | Record completed work or a short qualitative note | Useful ideas and finished work |
| Anxiety | 1-to-10 evening rating | Increased tension, rumination, or emotional volatility |
| Sleep quality | Morning rating and free-text description | Delayed sleep, lighter sleep, or next-day fatigue |
| Social ease | 1-to-10 rating after interactions | Greater connection versus overstimulation or withdrawal |
Compare without contaminating the test
Hold one protocol steady long enough to observe ordinary variation, then compare it with another framework. The appropriate duration depends on safety, tolerability, and the quality of your records. One disappointing day provides weak evidence, while repeated adverse effects justify stopping before the planned test is complete.
Review trends instead of isolated peaks. Examine timing patterns, changes on rest days, sleep disruption, emotional blunting, and whether the target outcome improves without creating a cost elsewhere. The MicroTrack's progress documentation guide provides a practical framework for turning daily notes into a searchable record.
A tracking app can reduce the work involved. MicroTrack supports Fadiman and Stamets-style calendars, custom schedules, dose timing, mood, focus, sleep, reflections, overrides, trend views, and CSV export. The useful output is a clearer comparison between cadence and outcome, rather than a perfect streak. Revisit the records after each protocol change and keep the schedule that supports the goal with the fewest unwanted effects.
Safety Considerations and Legal Realities
A careful psilocybin microdosing schedule cannot remove legal, medical, or product-related risk. Psilocybin remains illegal in many jurisdictions, with rules differing across national, state, provincial, and local authorities. Some places have created regulated or decriminalized pathways, but those changes do not erase federal restrictions or make possession lawful everywhere.
Treat legal status as part of the protocol. Do not transport, share, purchase, or possess psilocybin where prohibited. Check current information from an authoritative legal or government source rather than relying on an online schedule guide.
Know when not to experiment
People with a personal or family history of psychosis, schizophrenia, or bipolar disorder should avoid unsupervised psychedelic use. Pregnancy and nursing also warrant avoidance because effects remain uncertain. Anyone with cardiovascular concerns, high blood pressure, or a history of serious reactions should speak with a qualified clinician before considering exposure.
Medication combinations require professional review. SSRIs, MAOIs, lithium, and other psychiatric or cardiovascular medicines can change effects or create risks. A lack of dramatic symptoms does not establish that a combination is safe. Never stop prescribed medication to accommodate a microdosing plan.
Reduce preventable uncertainty
Mushroom potency can differ across species, batches, and individual pieces. Uneven material can turn an intended subtle session into a noticeably stronger experience. Where use is lawful, consistent preparation and reliable testing can reduce uncertainty, but neither removes it.
Avoid combining psilocybin with alcohol or other substances. Do not drive or operate machinery if you feel altered. If you proceed legally, tell a trusted person what you are doing. Stop if anxiety, paranoia, detachment from reality, escalating mood, sleep disruption, or other concerning symptoms appear, and seek medical help when needed.
A 2026 RAND-linked U.S. survey reported that about 10 million American adults microdosed psychedelics in 2025, while roughly 69% of past-year psilocybin users microdosed at least once. The coverage also reported that 64.6% of users did not test their substances, showing why a schedule cannot be separated from potency and source uncertainty. (RAND-linked survey coverage)
Broader participation does not make self-treatment clinically established. If depression, anxiety, mania, psychosis, or substance-use concerns influence the decision, professional care should take priority over schedule optimization. A review of psychedelic microdosing practices can provide research context, but it cannot replace individualized medical guidance.
MicroTrack provides a structured place to record dose days, rest days, skipped sessions, timing, mood, focus, sleep, side effects, and reflections while comparing Fadiman, Stamets-style, or custom rhythms. Visit MicroTrack to document the experiment instead of relying on memory or expectation.